Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer

Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer

Source: 
Pharmaceutical Business Review
snippet: 

Seagen and Astellas Pharma announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201.